CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy

Lignende værker

• WCN25-4036 Improved Outcomes with an Additional Rituximab Dose in Primary Membranous Nephropathy
  af: Vinod Kumar, et al.
  Udgivet: (2025-02-01)
• Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
  af: Maxime Teisseyre, et al.
  Udgivet: (2025-03-01)
• Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy
  af: Sengupta, Upal, et al.
  Udgivet: (2013)
• Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
  af: Maxime Teisseyre, et al.
  Udgivet: (2022-05-01)
• Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
  af: Wang, Xiao-Pei, et al.
  Udgivet: (2016)